Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer

Next Previous
Trial Profile

Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 May 2020 Results of a pooled analysis from four phase III trials: CONKO-001, JASPAC-01, ESPAC-4 and PRODIGE assessing prolongation of average survival time, prolongation of average event free time and time lived without an event presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 01 Feb 2020 Results of a retrospective biomarker study published in the Cancer Science.
  • 22 Feb 2018 Results (n=354) assessing health-related quality of life with of S-1 versus gemcitabine in patients with pancreatic cancer published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top